541 related articles for article (PubMed ID: 29645093)
21. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics.
Hamadani M; Ngoya M; Sureda A; Bashir Q; Litovich CA; Finel H; Chen Y; Boumendil A; Zain J; Castagna L; Cashen AF; Blaise D; Shadman M; Pastano R; Khimani F; Arat M; Dietrich S; Schmitz N; Glass B; Kharfan-Dabaja MA; Corradini P; Sauter CS; Montoto S; Kwon M; Herrera AF; Dreger P
Blood Adv; 2022 Feb; 6(3):920-930. PubMed ID: 34861680
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma.
Ida H; Inamoto Y; Fukuhara S; Maeshima AM; Takeda W; Hirakawa T; Kuno M; Aoki J; Tanaka T; Ito A; Kim SW; Izutsu K; Fukuda T
Hematol Oncol; 2021 Dec; 39(5):650-657. PubMed ID: 34431557
[TBL] [Abstract][Full Text] [Related]
23. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
[TBL] [Abstract][Full Text] [Related]
24. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
Fenske TS; Zhang MJ; Carreras J; Ayala E; Burns LJ; Cashen A; Costa LJ; Freytes CO; Gale RP; Hamadani M; Holmberg LA; Inwards DJ; Lazarus HM; Maziarz RT; Munker R; Perales MA; Rizzieri DA; Schouten HC; Smith SM; Waller EK; Wirk BM; Laport GG; Maloney DG; Montoto S; Hari PN
J Clin Oncol; 2014 Feb; 32(4):273-81. PubMed ID: 24344210
[TBL] [Abstract][Full Text] [Related]
25. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A
Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004
[TBL] [Abstract][Full Text] [Related]
26. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.
Avivi I; Canals C; Vernant JP; Wulf G; Nagler A; Hermine O; Petersen E; Yakoub-Agha I; Craddock C; Schattenberg A; Niederwieser D; Thomson K; Blaise D; Attal M; Pfreundschuh M; Passweg J; Russell N; Dreger P; Sureda A;
Bone Marrow Transplant; 2014 May; 49(5):671-8. PubMed ID: 24510071
[TBL] [Abstract][Full Text] [Related]
27. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
[TBL] [Abstract][Full Text] [Related]
28. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Hamadani M; Hari PN; Zhang Y; Carreras J; Akpek G; Aljurf MD; Ayala E; Bachanova V; Chen AI; Chen YB; Costa LJ; Fenske TS; Freytes CO; Ganguly S; Hertzberg MS; Holmberg LA; Inwards DJ; Kamble RT; Kanfer EJ; Lazarus HM; Marks DI; Nishihori T; Olsson R; Reddy NM; Rizzieri DA; Savani BN; Solh M; Vose JM; Wirk B; Maloney DG; Smith SM; Montoto S; Saber W; Alpdogan O; Cashen A; Dandoy C; Finke R; Gale R; Gibson J; Hsu JW; Janakiraman N; Laughlin MJ; Lill M; Cairo MS; Munker R; Rowlings PA; Schouten HC; Shea TC; Stiff PJ; Waller EK
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1729-36. PubMed ID: 25008330
[TBL] [Abstract][Full Text] [Related]
29. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
30. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Ingram W; Devereux S; Das-Gupta EP; Russell NH; Haynes AP; Byrne JL; Shaw BE; McMillan A; Gonzalez J; Ho A; Mufti GJ; Pagliuca A
Br J Haematol; 2008 Apr; 141(2):235-43. PubMed ID: 18318762
[TBL] [Abstract][Full Text] [Related]
31. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).
Bashey A; Owzar K; Johnson JL; Edwards PS; Kelly M; Baxter-Lowe LA; Devine S; Farag S; Hurd D; Ball E; McCarthy P; Lister J; Shea TC; Linker C
Biol Blood Marrow Transplant; 2011 Apr; 17(4):558-65. PubMed ID: 20674758
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission.
Poiré X; Labopin M; Polge E; Blaise D; Chevallier P; Maertens J; Deconinck E; Forcade E; Rambaldi A; Baerlocher GM; Zuckerman T; Volin L; Schouten HC; Ifrah N; Mohty M; Esteve J; Nagler A
Am J Hematol; 2019 Feb; 94(2):231-239. PubMed ID: 30456896
[TBL] [Abstract][Full Text] [Related]
34. The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.
Lunning MA; Migliacci JC; Hilden P; Devlin SM; Castro-Malaspina H; Giralt S; Perales MA; Zelenetz AD; Moskowitz CH; Sauter CS
Br J Haematol; 2016 Apr; 173(2):260-4. PubMed ID: 26847389
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.
Ito Y; Miyamoto T; Kamimura T; Takase K; Henzan H; Sugio Y; Kato K; Ohno Y; Eto T; Teshima T; Akashi K
Int J Hematol; 2013 Oct; 98(4):463-71. PubMed ID: 24043582
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
Parrondo RD; Reljic T; Iqbal M; Ayala E; Tun HW; Kharfan-Dabaja MA; Kumar A; Murthy HS
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e694-e711. PubMed ID: 32616401
[TBL] [Abstract][Full Text] [Related]
37. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
Ahmed S; Zhao Q; Hanel W; Qazilbash MH; Patel K; Narra R; Kansagra A; Iqbal M; Awan FT; Christian B; Jaglowski SM; Kharfan-Dabaja MA; Hamadani M; Epperla N
Hematol Oncol; 2022 Feb; 40(1):48-56. PubMed ID: 34763367
[TBL] [Abstract][Full Text] [Related]
38. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Dhakal B; Patel S; Girnius S; Bachegowda L; Fraser R; Davila O; Kanate AS; Assal A; Hanbali A; Bashey A; Pawarode A; Freytes CO; Lee C; Vesole D; Cornell RF; Hildebrandt GC; Murthy HS; Lazarus HM; Cerny J; Yared JA; Schriber J; Berdeja J; Stockerl-Goldstein K; Meehan K; Holmberg L; Solh M; Diaz MA; Kharfan-Dabaja MA; Farhadfar N; Bashir Q; Munker R; Olsson RF; Gale RP; Bayer RL; Seo S; Chhabra S; Hashmi S; Badawy SM; Nishihori T; Gonsalves W; Nieto Y; Efebera Y; Kumar S; Shah N; Qazilbash M; Hari P; D'Souza A
Leukemia; 2020 Dec; 34(12):3338-3347. PubMed ID: 32313109
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of autologous versus matched sibling donor stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia].
Lyu MN; Jiang EL; He Y; Yang DL; Ma QL; Pang AM; Zhai WH; Wei JL; Huang Y; Zhang GX; Zhang RL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):373-378. PubMed ID: 32536133
[No Abstract] [Full Text] [Related]
40. Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types.
Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Oncotarget; 2017 Jun; 8(25):41590-41604. PubMed ID: 28206975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
